Akoya (AKYA) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
August 8, 2022 4:05 PM EDTQ2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million
MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2022.
Akoya delivered another quarter of strong financial performance with record revenue and system placements in the second quarter, said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. This quarter was further highlighted by the announcement of our partnership with Acrivon Therapeutics and the demonstration of our RNA and multi-omics capabilities at AGBT.
... More